Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.

about

Risk of chemotherapy-induced febrile neutropenia by day of pegfilgrastim prophylaxis in US clinical practice from 2010 to 2015.

Item

http://www.wikidata.org/entity/Q47668200

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Risk of chemotherapy-induced f ...... al practice from 2010 to 2015.

@en

Risk of chemotherapy-induced f ...... al practice from 2010 to 2015.

@nl

type

Item

label

Risk of chemotherapy-induced f ...... al practice from 2010 to 2015.

@en

Risk of chemotherapy-induced f ...... al practice from 2010 to 2015.

@nl

prefLabel

Risk of chemotherapy-induced f ...... al practice from 2010 to 2015.

@en

Risk of chemotherapy-induced f ...... al practice from 2010 to 2015.

@nl

P1476

Risk of chemotherapy-induced f ...... al practice from 2010 to 2015.

@en

P2093

Alexander Lonshteyn

http://www.w3.org/2001/XMLSchema#string

David Chandler

http://www.w3.org/2001/XMLSchema#string

Derek Weycker

http://www.w3.org/2001/XMLSchema#string

Mark Bensink

http://www.w3.org/2001/XMLSchema#string

Robin Doroff

http://www.w3.org/2001/XMLSchema#string

P2860

Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.

30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer: cohort study

Pegfilgrastim on the Same Day Versus Next Day of Chemotherapy in Patients With Breast Cancer, Non-Small-Cell Lung Cancer, Ovarian Cancer, and Non-Hodgkin's Lymphoma: Results of Four Multicenter, Double-Blind, Randomized Phase II Studies.

2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.

First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: a multicenter, double-blind, placebo-controlled phase III study.

Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.

Technical evaluation of methods for identifying chemotherapy-induced febrile neutropenia in healthcare claims databases.

Front-line Treatment with Gemcitabine, Paclitaxel, and Doxorubicin for Patients With Unresectable or Metastatic Urothelial Cancer and Poor Renal Function: Final Results from a Phase II Study

Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?

Trajectory of absolute neutrophil counts in patients treated with pegfilgrastim on the day of chemotherapy versus the day after chemotherapy.

P304

2107-2113

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/03007995.2017.1386858

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-09-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28958157

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy-induced febrile neutropenia